1
|
Rastrelli M, Tropea S, Rossi CR and
Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis,
diagnosis and classification. In Vivo. 28:1005–1011.
2014.PubMed/NCBI
|
2
|
Trotter SC, Sroa N, Winkelmann RR, Olencki
T and Bechtel M: A global review of melanoma follow-up guidelines.
J Clin Aesthet Dermatol. 6:18–26. 2013.PubMed/NCBI
|
3
|
Linos E, Swetter SM, Cockburn MG, Colditz
GA and Clarke CA: Increasing burden of melanoma in the United
States. J Invest Dermatol. 129:1666–1674. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Populo H, Soares P and Lopes JM: Insights
into melanoma: targeting the mTOR pathway for therapeutics. Expert
Opin Ther Targets. 16:689–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Liu S, Kumar SM, Lu H, Liu A, Yang R,
Pushparajan A, Guo W and Xu X: MicroRNA-9 up-regulates E-cadherin
through inhibition of NF-κB1-Snail1 pathway in melanoma. J Pathol.
226:61–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Liu N, Sun Q, Chen J, Li J, Zeng Y, Zhai
S, Li P, Wang B and Wang X: MicroRNA-9 suppresses uveal melanoma
cell migration and invasion through the NF-κB1 pathway. Oncol Rep.
28:961–968. 2012.PubMed/NCBI
|
10
|
Zhao G, Li Q, Wang A and Jiao J: YY1
regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis. J Exp
Clin Cancer Res. 34:662015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Opitz CA and Heiland I: Dynamics of
NAD-metabolism: Everything but constant. Biochem Soc Trans.
43:1127–1132. 2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Qiu G, Li X, Che X, Wei C, He S, Lu J, Jia
Z, Pang K and Fan L: SIRT1 is a regulator of autophagy:
Implications in gastric cancer progression and treatment. FEBS
Lett. 589:2034–2042. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang X, Chen S, Cheng M, Cao F and Cheng
Y: The expression and correlation of SIRT1 and Phospho-SIRT1 in
colorectal cancer. Int J Clin Exp Med. 8:809–817. 2015.PubMed/NCBI
|
14
|
Lin L, Zheng X, Qiu C, Dongol S, Lv Q,
Jiang J, Kong B and Wang C: SIRT1 promotes endometrial tumor growth
by targeting SREBP1 and lipogenesis. Oncol Rep. 32:2831–2835.
2014.PubMed/NCBI
|
15
|
Li L and Bhatia R: Role of SIRT1 in the
growth and regulation of normal hematopoietic and leukemia stem
cells. Curr Opin Hematol. 22:324–329. 2015.PubMed/NCBI
|
16
|
Hu Z, Fan H, Lv G, Zhou Q, Yang B, Zheng J
and Cao W: 5-Aminolevulinic acid-mediated sonodynamic therapy
induces anti-tumor effects in malignant melanoma via
p53-miR-34a-Sirt1 axis. J Dermatol Sci. 79:155–162. 2015.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Wilking MJ, Singh C, Nihal M, Zhong W and
Ahmad N: SIRT1 deacetylase is overexpressed in human melanoma and
its small molecule inhibition imparts anti-proliferative response
via p53 activation. Arch Biochem Biophys. 563:94–100. 2014.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Ohanna M, Bonet C, Bille K, Allegra M,
Davidson I, Bahadoran P, Lacour JP, Ballotti R and Bertolotto C:
SIRT1 promotes proliferation and inhibits the senescence-like
phenotype in human melanoma cells. Oncotarget. 5:2085–2095. 2014.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Kozubek J, Ma Z, Fleming E, Duggan T, Wu
R, Shin DG and Dadras SS: In-depth characterization of microRNA
transcriptome in melanoma. PLoS One. 8:e726992013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xu D, Tan J, Zhou M, Jiang B, Xie H, Nie
X, Xia K and Zhou J: Let-7b and microRNA-199a inhibit the
proliferation of B16F10 melanoma cells. Oncol Lett. 4:941–946.
2012.PubMed/NCBI
|
22
|
Strong AM Poenitzsch, Setaluri V and
Spiegelman VS: microRNA-340 as a modulator of RAS-RAF-MAPK
signaling in melanoma. Arch Biochem Biophys. 563:118–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Bai J, Zhang Z, Li X and Liu H:
MicroRNA-365 inhibits growth, invasion and metastasis of malignant
melanoma by targeting NRP1 expression. Int J Clin Exp Pathol.
8:4913–4922. 2015.PubMed/NCBI
|
24
|
Chen J, Feilotter HE, Paré GC, Zhang X,
Pemberton JG, Garady C, Lai D, Yang X and Tron VA: MicroRNA-193b
represses cell proliferation and regulates cyclin D1 in melanoma.
Am J Pathol. 176:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
26
|
Wu Y, Meng X, Huang C and Li J: Emerging
role of silent information regulator 1 (SIRT1) in hepatocellular
carcinoma: A potential therapeutic target. Tumour Biol.
36:4063–4074. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Qu Y, Zhang J, Wu S, Li B, Liu S and Cheng
J: SIRT1 promotes proliferation and inhibits apoptosis of human
malignant glioma cell lines. Neurosci Lett. 525:168–172. 2012.
View Article : Google Scholar : PubMed/NCBI
|